HDAC6 Inhibitor key unlocking the potential of CD20 cancer therapy.

Unlock Cancer Treatment: How HDAC6 Inhibition Supercharges Anti-CD20 Therapy

Author's portrait.
Kai Mendoza in Health & Wellness June 2025 • 5 min read.

"A breakthrough study reveals how blocking HDAC6, an enzyme involved in protein regulation, can significantly boost the effectiveness of anti-CD20 monoclonal antibodies against blood cancers."


For years, anti-CD20 monoclonal antibodies have revolutionized the treatment of blood cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, resistance to these therapies remains a significant hurdle for many patients. Scientists are constantly seeking ways to enhance the effectiveness of these antibodies, and a recent study published in "Blood" sheds light on a promising new approach.

The study, led by researchers at the Medical University of Warsaw, Poland, unveils the critical role of HDAC6 (histone deacetylase 6) in regulating CD20 levels on cancer cells. CD20 is a protein found on the surface of B cells, including cancerous ones, and is the target of anti-CD20 antibodies like rituximab. When these antibodies bind to CD20, they trigger the destruction of the cancer cells. However, if CD20 levels are low, the antibodies are less effective.

The groundbreaking research demonstrates that inhibiting HDAC6 can significantly increase CD20 levels on cancer cells, making them more vulnerable to anti-CD20 antibody therapy. This discovery opens up new avenues for developing combination therapies that could overcome resistance and improve outcomes for patients with blood cancers. Let's dive deeper into how this innovative approach works and what it could mean for the future of cancer treatment.

HDAC6: The Key to Unlocking CD20 Potential

HDAC6 Inhibitor key unlocking the potential of CD20 cancer therapy.

HDAC6 is an enzyme that plays a crucial role in regulating the acetylation status of proteins within the cell. Acetylation is a process that modifies protein function, and HDAC6 specifically targets proteins in the cytoplasm, the area outside the cell's nucleus. Interestingly, HDAC6 is involved in protein degradation, a process where cells break down and remove misfolded or damaged proteins. In cancer cells, this degradation process can affect the levels of key proteins like CD20.

The researchers discovered that HDAC6 inhibition leads to an increase in CD20 protein synthesis. This means that the cancer cells are producing more CD20, making them more susceptible to the effects of anti-CD20 antibodies. What's particularly exciting is that this increase in CD20 levels doesn't seem to be related to changes in gene expression. Instead, HDAC6 inhibition appears to be enhancing the translation of CD20 mRNA, the molecule that carries the instructions for building the CD20 protein.

Here's a summary of the key findings:
  • HDAC6 Inhibition: Specific inhibitors like tubacin, tubastatin A, and ricolinostat significantly increased CD20 levels on cancer cells.
  • Enhanced Efficacy: HDAC6 inhibition boosted the effectiveness of anti-CD20 antibodies like rituximab and ofatumumab in killing cancer cells.
  • Mechanism of Action: HDAC6 inhibition increased CD20 protein synthesis without affecting CD20 gene expression.
  • In Vivo Success: In mice, HDAC6 inhibition improved the survival rates of those treated with rituximab.
To confirm these findings, the researchers used a variety of techniques, including experiments with cancer cell lines, primary cells from CLL patients, and even mouse models. They found that HDAC6 inhibition consistently led to increased CD20 levels and enhanced the efficacy of anti-CD20 antibodies. These results strongly suggest that HDAC6 inhibition is a promising strategy for overcoming resistance to anti-CD20 therapy and improving outcomes for patients with blood cancers.

The Future of Blood Cancer Therapy: Combination Approaches

This research provides a strong rationale for exploring combination therapies that combine HDAC6 inhibitors with anti-CD20 antibodies. By increasing CD20 levels on cancer cells, HDAC6 inhibitors can make these cells more vulnerable to the effects of anti-CD20 antibodies, potentially overcoming resistance and improving outcomes. Several HDAC6 inhibitors are already in clinical development for various cancers, and these findings suggest that they could also be valuable tools in the fight against blood cancers. While further research is needed to fully understand the mechanisms involved and to identify the optimal combination strategies, this study represents a significant step forward in the quest for more effective cancer treatments. As research progresses, these combined therapies could offer new hope and improved survival rates for patients battling blood cancers.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What is the role of HDAC6 in the context of anti-CD20 therapy for blood cancers?

HDAC6 (histone deacetylase 6) plays a critical role in regulating the levels of CD20, a protein found on the surface of B cells, including cancerous ones. The study shows that inhibiting HDAC6 leads to an increase in CD20 levels on cancer cells. This makes the cancer cells more susceptible to anti-CD20 antibodies, like rituximab, enhancing the effectiveness of the therapy. HDAC6's impact isn't tied to gene expression changes, instead enhancing CD20 protein synthesis and translation of CD20 mRNA, which is a new way to boost treatment effectiveness.

2

How does HDAC6 inhibition enhance the effectiveness of anti-CD20 antibodies in treating blood cancers?

HDAC6 inhibition boosts the efficacy of anti-CD20 antibodies by increasing the levels of CD20 protein on cancer cells. Anti-CD20 antibodies, such as rituximab, target the CD20 protein, which is present on the surface of cancerous B cells. When HDAC6 is inhibited, it leads to a higher production of CD20. This increased CD20 presence makes the cancer cells more vulnerable to the anti-CD20 antibodies. Therefore, the antibodies can more effectively bind to and destroy the cancer cells. This approach could potentially overcome resistance to existing therapies and improve treatment outcomes for patients with blood cancers.

3

What are the implications of using HDAC6 inhibitors in combination with anti-CD20 antibodies for blood cancer treatment?

Using HDAC6 inhibitors in combination with anti-CD20 antibodies offers the potential to significantly improve blood cancer treatment. By increasing CD20 levels on cancer cells, HDAC6 inhibitors can make the cells more susceptible to anti-CD20 antibodies. This approach could overcome resistance to anti-CD20 therapy and improve the outcomes for patients. The research suggests a new strategy for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, potentially leading to improved survival rates. Several HDAC6 inhibitors are already in clinical development, which could accelerate the transition to clinical trials for combination therapies.

4

Are there specific HDAC6 inhibitors mentioned, and how were they tested in the study?

Yes, the study specifically mentions and tested several HDAC6 inhibitors, including tubacin, tubastatin A, and ricolinostat. These inhibitors were used to target and block the activity of HDAC6. Researchers used a variety of techniques, including experiments with cancer cell lines, primary cells from CLL patients, and even mouse models to confirm the findings. The results consistently showed that HDAC6 inhibition increased CD20 levels and improved the effectiveness of anti-CD20 antibodies in killing cancer cells, leading to in vivo success in improving survival rates in mice treated with rituximab.

5

What are the future directions for this research, and what is the potential impact on blood cancer treatment?

The future of this research involves exploring combination therapies that combine HDAC6 inhibitors with anti-CD20 antibodies. This approach aims to enhance the efficacy of anti-CD20 therapies by increasing the levels of CD20 on cancer cells. Further research is needed to understand the mechanisms involved and to identify the best combination strategies. The potential impact on blood cancer treatment is significant, offering new hope and improved survival rates for patients battling blood cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia. As research progresses, these combined therapies could overcome resistance to existing treatments and offer new hope.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.